Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HNO·2026
Same author

[Facial fillers: evidence base, anatomical principles, materials, risks, techniques, and future perspectives].

HNO·2026
Same author

Disease-specificity in correlations between speech audiometry, hearing-related quality of life, and varying calculation methods for pure tone average in middle ear diseases.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026
Same author

Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC.

BMC cancer·2026
Same author

Frequency of electrode migration and other device-related complications in a large single-center cochlear implant cohort.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026
Same author

Angular Insertion Depth for Cochlear Implantation: A Comparative Analysis on Precision of CT, MRI, and x-Ray.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same journal

Laryngeal Injuries Following General Endotracheal Anesthesia: A Case Series.

The Annals of otology, rhinology, and laryngology·2026
Same journal

Clinical and Voice Outcome Differences in Vocal Cord Cysts with and Without Sulcus Vocalis: Insights From a Tertiary Center in Saudi Arabia.

The Annals of otology, rhinology, and laryngology·2026
Same journal

Bioabsorbable Stenting in a Case of Severe Pediatric Posterior Glottic Stenosis.

The Annals of otology, rhinology, and laryngology·2026
Same journal

Efficacy and Safety of Finafloxacin Otic Suspension, 0.3% for the Treatment of Acute Otitis Externa: Results from two Phase III Randomized Clinical Studies.

The Annals of otology, rhinology, and laryngology·2026
Same journal

Evaluation Of the Expression Levels Of SerpinB3/B4/B10, Interleukin-17 As Biomarkers For Chronic Rhinosinusitis With Nasal Polyps.

The Annals of otology, rhinology, and laryngology·2026
Same journal

Correlation of Patient-Reported Symptoms With Rhinogram Features Beyond Simple Airway Resistance.

The Annals of otology, rhinology, and laryngology·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Etanercept prevents decrease of cochlear blood flow dose-dependently caused by tumor necrosis factor alpha.

Friedrich Ihler1, Kariem Sharaf, Mattis Bertlich

  • 1Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilians-University Munich, Germany.

The Annals of Otology, Rhinology, and Laryngology
|August 20, 2013
PubMed
Summary
This summary is machine-generated.

Tumor necrosis factor alpha (TNF-alpha) significantly reduces cochlear blood flow in a dose-dependent manner. Etanercept effectively blocks this TNF-alpha-induced decrease in cochlear microcirculation.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Related Experiment Videos

Last Updated: May 8, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Area of Science:

  • Otoacoustic emissions
  • Auditory neuroscience
  • Inflammation research

Background:

  • Tumor necrosis factor alpha (TNF-alpha) plays a key role in cochlear inflammation and microcirculation.
  • Understanding TNF-alpha's impact on the inner ear is crucial for developing treatments for hearing disorders.

Purpose of the Study:

  • To quantify the effect of increased TNF-alpha on cochlear microcirculation.
  • To investigate the interaction between TNF-alpha and etanercept in modulating cochlear blood flow.

Main Methods:

  • Intravital microscopy was used to assess cochlear lateral wall vessels in guinea pigs.
  • TNF-alpha at varying concentrations (5.0, 0.5, 0.05 ng/mL) or placebo was applied.
  • Etanercept pretreatment followed by TNF-alpha administration was evaluated.

Main Results:

  • A high concentration of TNF-alpha (5.0 ng/mL) significantly decreased cochlear blood flow (p < 0.01).
  • Lower TNF-alpha concentrations and placebo did not cause significant changes.
  • Etanercept pretreatment prevented the TNF-alpha-induced reduction in cochlear blood flow.

Conclusions:

  • The inhibitory effect of TNF-alpha on cochlear blood flow is dose-dependent.
  • Etanercept effectively counteracts the negative impact of TNF-alpha on cochlear microcirculation.